Categories Earnings, Retail

Shopify’s (SHOP) Q4 results beat market expectations

Shopify Inc. (NYSE: SHOP) topped analysts’ expectations on revenue and earnings for the fourth quarter of 2019, sending the stock soaring 9% in premarket hours on Wednesday. Analysts had forecast earnings of $0.24 per share on revenue of $482 million.

Total revenue jumped 47% year-over-year to $505.2 million, aided by growth in monthly recurring revenue (MRR) and gross merchandise volume (GMV).  

Shopify topped Q4 2019 revenue and earnings estimates

Net income was $0.8 million, or $0.01 per share, compared to a net loss of $1.5 million, or $0.01 per share, in the prior-year quarter. Adjusted net income was $50 million, or $0.43 per share.  

Shopify posted double-digit revenue increases in its Subscription Solutions and Merchant Solutions divisions. The company’s investments in its product improvement initiatives and expansion efforts helped bring more merchants onto the platform leading to a growth in monthly recurring revenue.

Also read: Shopify Q4 2019 Earnings Preview

The company has been making progress on the integration of 6 River Systems with its Shopify Fulfilment Network during the quarter. In addition, the adoption of Shopify Shipping has increased with 45% of merchants in the US and Canada using the service in the fourth quarter. This number was less than 40% in the same period last year.  

Shopify launched 13 new language capabilities on its platform including Danish, Finnish, Hindi and Thai and rolled out Shopify Payments in four more countries, expanding its footprint to 15 countries.  

For the first quarter of 2020, Shopify expects revenues of $440 million to $446 million. For the full year of 2020, Shopify expects revenues of $2.13 billion to $2.16 billion.  

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top